BIOtech Now
Brian Newell
$1.3 trillion in economic output. Support for roughly 4.2 million jobs. The creation of more than 11,000 start-up companies. More than 200 new drugs and vaccines. This is the legacy of the Bayh-Dole Act, which for more than 35 years has empowered universities, small businesses and non-profit institutions to take ownership of innovations discovered through basic federally-funded research. Why? So these basic innovations may be developed into approved therapies that reduce suffering, treat the sick and improve the lives of patients.
And this is what’s at stake if certain activists are successful in undermining the law. That’s why BIO is releasing its latest infographic, which highlights the tremendous success of the Bayh-Dole Act and explains why policymakers must reject any effort that would weaken the law. To download the infographic, click the image below.
Powered by WPeMatico